• Levofloxacin: Applied Workflows for DNA Replication and Bone

  2026-05-14

  Levofloxacin, a synthetic fluoroquinolone antibiotic, enables high-fidelity modeling of bacterial DNA replication inhibition and provides unique insights into osteoblast and chondrocyte assays. This article translates recent resistance findings and detailed experimental workflows into actionable guidance for optimizing cell-based, microbiological, and cartilage metabolism studies.

• Cefodizime: Third-Generation Cephalosporin for Broad-Spectru

  2026-05-14

  Cefodizime is a third-generation cephalosporin antibiotic with robust, broad-spectrum activity against Gram-positive and Gram-negative pathogens. Its β-lactamase stability and immunomodulatory effects support its use in microbiology research and infectious disease modeling. Key pharmacokinetic properties and validated benchmarks make Cefodizime a cornerstone for respiratory and urinary tract infection studies.

• Pentoxifylline: Applied Protocols for Inflammation Research

  2026-05-13

  Pentoxifylline, a proven phosphodiesterase inhibitor, enables precise modulation of inflammatory pathways and immune responses across diverse in vitro and in vivo models. This article translates primary evidence and workflow innovations into actionable protocols and troubleshooting strategies, with a focus on optimizing anti-inflammatory assays and cytokine suppression.

• Ziprasidone Hydrochloride: GOT1 Inhibition and Tumor Metabol

  2026-05-13

  Explore how Ziprasidone HCl extends beyond antipsychotic research to disrupt tumor metabolism via GOT1 inhibition. This article delivers advanced insights for oncology scientists seeking translational applications of Ziprasidone Hydrochloride.

• Aztreonam: Optimizing Gram-Negative Assays with Monocyclic β

  2026-05-12

  Aztreonam, a monocyclic β-lactam antibiotic, is a precision tool against Gram-negative aerobic bacteria, enabling advanced resistance and metabolic studies. This article delivers actionable protocols, troubleshooting insights, and data-driven guidance for maximizing reproducibility and impact in Gram-negative research.

• Redefining N-Type Ca Channel Blockade: Insights from v-Agato

  2026-05-12

  Sidach and Mintz's 2000 study demonstrates that the spider toxin v-agatoxin-IVA, long considered a selective P-type calcium channel blocker, also inhibits N-type channels at higher concentrations. This finding challenges established classification schemes and informs the design of neurophysiological experiments using calcium channel antagonists.

• Ceftazidime: Mechanism, Evidence & Research Parameters

  2026-05-11

  Ceftazidime, a third-generation cephalosporin, is a β-lactamase-resistant antibiotic with potent activity against Gram-negative bacteria, notably Pseudomonas aeruginosa. This article provides a structured review of its biological rationale, mechanism, research evidence, and workflow integration for bacterial infection studies.

• Cefazedone (Refosporen): Applied Workflows and Assay Optimiz

  2026-05-11

  Cefazedone (Refosporen) empowers researchers to perform reproducible antibacterial testing and pharmacokinetic profiling against both Gram-positive and Gram-negative pathogens. This article delivers stepwise protocol enhancements, troubleshooting strategies, and actionable insights based on the latest validated LC–MS/MS methodologies. Leverage APExBIO’s trusted supply to ensure data integrity from bench to publication.

• Levofloxacin: Synthetic Fluoroquinolone Antibiotic in Advanc

  2026-05-10

  Levofloxacin stands apart as a synthetic fluoroquinolone antibiotic that not only targets bacterial DNA replication but also serves as a powerful probe in bone and cartilage research. This article delivers actionable guidance for integrating Levofloxacin into bacterial, osteoblast, and chondrocyte assays—complete with protocol parameters, troubleshooting, and cross-domain insights.

• Bone Transport Enhances Diabetic Foot Ulcer Repair via TGF-β

  2026-05-09

  This study elucidates how bone transport (BT) accelerates healing of diabetic foot ulcers by activating the TGF-β1/TGFBR1-mediated coupling of angiogenesis and immune modulation. The findings clarify a key osteo-immune signaling mechanism, suggesting targeted manipulation of the TGF-beta1 pathway as a promising strategy in chronic wound repair.

• BH3 Mimetics Target Senescent Breast Cancer After Chemothera

  2026-05-09

  This study demonstrates that BH3 mimetics, specifically BCL-XL inhibitors, can selectively eliminate chemotherapy-induced senescent cells in TP53 wild-type breast cancer. The findings highlight a promising strategy to overcome residual disease and improve therapeutic outcomes by targeting the survival mechanisms of senescent tumor cells.

• HRP Goat Anti-Mouse IgG (H+L) Antibody: Protocol and QC Guid

  2026-05-08

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU: K1221) provides reliable, high-sensitivity detection of mouse primary antibodies in immunodetection workflows such as Western blot, ELISA, IHC, and ICC. It should be used strictly for mouse IgG detection; applications outside this scope or targeting non-mouse immunoglobulins are not supported by current product specifications.

• Synergy of Copper and Hexetidine Against Oral Streptococci:

  2026-05-07

  This study demonstrates a pronounced synergistic antibacterial effect between copper and hexetidine against Streptococcus sobrinus and Streptococcus sanguis, key organisms in dental plaque formation. The research provides quantitative evidence for the efficacy of combination antimicrobial strategies and informs the design of future antibacterial assays targeting oral pathogens.

• Chronic NAD Depletion Triggers cGAS-STING Interferon Respons

  2026-05-07

  This study reveals that chronic cellular NAD depletion, induced by nicotinamide withdrawal, causes mitochondrial DNA leakage and activates a STING-mediated, viral infection-like type I interferon response. The findings clarify how metabolic stress can engage innate immune pathways, offering new directions for research on aging, inflammation, and disease.

• PK/PD Evaluation of Cefazedone in Community-Acquired Pneumon

  2026-05-06

  This study rigorously evaluates the pharmacokinetic and pharmacodynamic properties of intravenous Cefazedone (Refosporen) in patients with mild to moderate community-acquired pneumonia (CAP). Its findings confirm the rationality of a 2 g q12h regimen for achieving therapeutic drug levels and clinical efficacy, directly informing both clinical protocols and laboratory research.

448 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page